A carregar...
Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)
BACKGROUND: Brodalumab is efficacious for the treatment of moderate‐to‐severe plaque psoriasis through 52 weeks. OBJECTIVES: To evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment. METHODS: At baseline, patients were randomized to brodalum...
Na minha lista:
| Publicado no: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7754427/ https://ncbi.nlm.nih.gov/pubmed/32286683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.19132 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|